RxDoctor Payments DataLook up a doctor →

David Zetter, MD

General Practice · Arlington, KYNPI 1598711756

Payments from drug & device makers

$11,883in general payments, 2019–2025

Across 869 payments — averaging $13.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Johnson & Johnson$1K
  • Novo Nordisk$860
  • Lilly USA, LLC$824
  • Boehringer Ingelheim$638
  • Sunovion Pharmaceuticals Inc.$634
  • plus $6K from 42 others

What the payments were for

  • Food & beverage$11,874100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,883 in reported general payments places this provider in the 95th percentile of 1,155 general practice providers in Kentucky.

See all general practice providers in Kentucky

Medicare billing

Part B allowed, 2024
$425,418
Medicare patients
1,142
Services billed
22,074

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban2,535$875,219
IngrezzaValbenazine Tosylate54$249,779
OzempicSemaglutide192$224,325
JardianceEmpagliflozin440$203,068
EntrestoSacubitril/Valsartan404$166,803
JanuviaSitagliptin Phosphate353$165,730
XareltoRivaroxaban299$122,030
TrulicityDulaglutide149$112,864
Trelegy ElliptaFluticasone/Umeclidin/Vilanter136$99,160
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog401$83,804
Cimzia (2 Pack)Certolizumab Pegol13$78,561
Breztri AerosphereBudesonide/Glycopyr/Formoterol93$74,016
Memantine Hcl1,047$66,332
LinzessLinaclotide102$63,424
Invega SustennaPaliperidone Palmitate19$63,051

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$518$875,2192,535 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$638$294,181657 claims
Novo NordiskOzempic, Rybelsus$860$286,300237 claims
Neurocrine Biosciences, Inc.Ingrezza$290$249,77954 claims
Johnson & JohnsonXarelto, Invega Sustenna, Procrit$1,200$225,644362 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$133$187,680383 claims
Lilly USA, LLCTrulicity, Mounjaro$824$167,404200 claims
NovartisEntresto$1,364$166,803404 claims
MerckJanuvia$302$165,730353 claims
AstraZenecaBreztri Aerosphere, Farxiga$625$127,700260 claims
AbbVieLinzess, Qulipta$391$89,860139 claims
Astellas Pharma US IncMyrbetriq$279$55,240153 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,155 general practice providers in Kentucky.

Other general practice in Arlington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →